EuBiologics Co., Ltd.

Total Valuation

EuBiologics Co., Ltd. carries a market capitalization of 362.58B, placing it among publicly traded companies globally. Its enterprise value stands at 413.32B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Valuation Ratios

EuBiologics Co., Ltd. trades at a trailing price-to-earnings ratio of 16.83. The price-to-sales ratio is 3.92, and the price-to-book ratio stands at 3.48.

Enterprise Valuation

On an enterprise value basis, EuBiologics Co., Ltd. trades at an EV/EBITDA multiple of 8.99 and an EV/FCF ratio of 7.86. The EV/Sales ratio of 3.30 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 8.99 provides insight into valuation relative to core operating earnings.

Financial Position

EuBiologics Co., Ltd. maintains a current ratio of 3.99, meaning it holds 4.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.43, indicating conservative leverage, while an interest coverage ratio of 51.37 demonstrates strong ability to service its debt obligations.

Financial Efficiency

EuBiologics Co., Ltd. posts a return on equity of 23.08 and a return on invested capital of 19.04.

Taxes

Over the trailing twelve months, EuBiologics Co., Ltd. has paid 12.54B in income taxes, reflecting an effective tax rate of 30.03.

Stock Price Statistics

EuBiologics Co., Ltd.'s stock has declined approximately -24.36975% over the past 52 weeks. The 50-day moving average sits at 12,603.00, while the 200-day moving average is 12,875.35.

Income Statement

Over the trailing twelve months, EuBiologics Co., Ltd. generated 125.33B in revenue and converted that into 29.23B in net income, yielding earnings per share of 796.60. EBITDA reached 45.95B, while operating income came in at 45.95B.

Balance Sheet

EuBiologics Co., Ltd. holds 79.33B in cash and equivalents against 764.68M in total debt, resulting in a net debt position of -21.31B. Total book value stands at 141.30B, with working capital of 101.37B providing operational flexibility.

Cash Flow

EuBiologics Co., Ltd. produced 34.91B in operating cash flow over the past twelve months. After subtracting -17.07B in capital expenditures, free cash flow totaled 17.84B - equivalent to 487.01 per share.

Margins

EuBiologics Co., Ltd. operates with a gross margin of 58.20, reflecting its pricing power and cost economics. The operating margin of 36.67 and net profit margin of 23.32 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

EuBiologics Co., Ltd.'s most recent stock split took place on November 12, 2020 with a 500:517 split ratio.

Scores

EuBiologics Co., Ltd. posts an Altman Z-Score of 7.92, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.